Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Revenues:
Product royalty revenues	$ 1,773,215	$ 1,082,742	$ 2,716,452
Research revenue		13,375	227,668
Research and development reimbursements	2,782,830
Contract revenue	6,799,838	53,446,309	318,800
Total revenues	11,355,883	54,542,426	3,262,920
Cost of product royalties	2,082,183	1,909,785	1,756,629
Expenses:
Research and development	53,326,777	35,365,662	20,805,177
General and administrative	12,302,364	10,114,689	7,608,090
Related party general and administrative	46,500	90,500	81,000
Total expenses	65,675,641	45,570,851	28,494,267
(Loss) income from operations	(56,401,941)	7,061,790	(26,987,976)
Interest (expense) income, net	(902,658)	280,709	188,701
Derivative gain (loss)	121,228	(5,594,152)	3,463,453
Other (expenses) income, net	(210,242)	32,954	10,706
Total nonoperating Income (Expense)	(991,672)	(5,280,489)	3,662,860
(Loss) income before taxes	(57,393,613)	1,781,301	(23,325,116)
Income tax expense		(129,120)
Net (loss) income attributable to common stockholders	$ (57,393,613)	$ 1,652,181	$ (23,325,116)
Basic:
Weighted average common stock shares outstanding	37,941,044	30,546,581	28,322,477
Basic earnings per share	$ (1.51)	$ 0.05	$ (0.82)
Diluted:
Diluted weighted average common stock shares outstanding	37,941,044	30,689,235	28,322,477
Diluted earnings per share	$ (1.51)	$ 0.05	$ (0.82)